Daptomycin
Generic name
Daptomycin
Brand name
ATC Code
J01XX09
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric cSSTI Patients (1 to 17 Years of Age):
| Age Range | 1 to <2 years | 2-6 years (N=7) | 7-11 years (N=2) | 12-17 years (N=6) |
| Dose Infusion Time |
10 mg/kg 60 minutes |
9 mg/kg 60 minutes |
7 mg/kg 30 minutes |
5 mg/kg 30 minutes |
| Cmax (µg/ml) | 79.2 | 81.9 (21.6) | 64.9, 74.4 | 62.4 (10.4) |
| Apparent t1/2 (hr) | 5.04 | 3.8 (0.3) | 4.6 | 5.3 (1.6) |
| CL/wt (ml/hr/kg) | 21.5 | 21.4 (5.0) | 16.0 | 13.3 (2.9) |
Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric SAB Patients (1 to 17 Years of Age):
| Age Range | 1 to 6 years (N=19) | 7-11 years (N=19) | 12-17 years (N=13) |
| Dose Infusion Time |
12 mg/kg 60 minutes |
9 mg/kg 30 minutes |
7 mg/kg 30 minutes |
| Cmax (µg/ml) | 106 (12.8) | 104 (14.5) | 104 (35.5) |
| Apparent t1/2 (hr) | 5.1 (0.6) | 6.0 (0.8) | 7.5 (2.3) |
| CL/wt (ml/hr/kg) | 19.9 (3.4) | 15.9 (2.8) | 12.4 (3.9) |
[EPAR Cubicin]
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Infections of the skin and soft tissues without bacteraemia |
|---|
|
| Infections of the skin and soft tissues with S. Aureus bacteraemia |
|---|
|
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
No adjustment requiredGFR 30-50 ml/min/1.73 m2
No adjustment requiredGFR 10-30 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 48 uurGFR < 10 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 48 uurPatients on dialysis
On dialysis days, daptomycin should if possible be administered after the dialysis.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Do not administer to children < 1 year due to possible effects on the musculoskeletal system and/or nervous system, as observed in animals. The clinical relevance of these findings is unknown.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
OTHER ANTIBACTERIALS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Glycopeptide antibacterials | ||
|---|---|---|
| J01XA04 | ||
| J01XA02 | ||
| J01XA01 | ||
| Polymyxins | ||
|---|---|---|
| J01XB01 | ||
| Steroid antibacterials | ||
|---|---|---|
| J01XC01 | ||
| Nitrofuran derivatives | ||
|---|---|---|
| J01XE01 | ||
| Other antibacterials | ||
|---|---|---|
| J01XX08 | ||
| J01XX01 | ||
Reference
- Novartis Europharm Limited, SmPC Cubicin (EU/1/05/328/001-004) 04-01-2018, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
